December 18, 2020 An unplanned interim analysis from a study that was halted in the aftermath of concerns about paclitaxel shows no difference in rates of long-term all-cause mortality between patients with PAD treated with coated or uncoated devices, regardless of the extent of limb disease. The SWEDEPAD trialists, along with those from the BASIL-3 study, paused recruitment following publication of a meta-analysis in late 2018 by Konstantinos Katsanos, MD, PhD (Patras University Hospital, Rion, Greece), and colleagues. The controversial meta-analysis reported a 68% relative increase in risk of all-cause death with paclitaxel-coated devices versus uncoated devices at 2 years and a 93% relative risk increase by 5 years in those with femoral and/or popliteal artery disease.